Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Japan
Clinical trial register · Japan

Clinical Trials in Japan

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Sapporo 12 Yokohama 10 Fukuoka 10 Nagoya 9 Tokyo 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca196 Eli Lilly and Company118 Novartis Pharmaceuticals106 AbbVie100 Merck Sharp & Dohme LLC100 Pfizer99 Janssen Research & Development, LLC78 GlaxoSmithKline74 Bristol-Myers Squibb69 China-Japan Friendship Hospital69 Boehringer Ingelheim52 Sanofi51 Takeda49 Amgen49 Hoffmann-La Roche47 Daiichi Sankyo43 Novo Nordisk A/S32 Bayer30 Ono Pharmaceutical Co., Ltd.27 Genmab21 Alexion Pharmaceuticals, Inc.19 Incyte Corporation19 Regeneron Pharmaceuticals18 Astellas Pharma Global Development, Inc.17 argenx16 Show all 535 Clear sponsor filter
Site location
Sapporo12 Yokohama10 Fukuoka10 Nagoya9 Tokyo8 Kodaira6 Kyoto6 Kashiwa6 Sendai5 Sagamihara5 Higashi-Matsuyama5 Okayama5 Kanazawa5 Kobe5 Kamakura5 Habikino4 Sakai4 Tachikawa4 Hiroshima4 Kōriyama4 Asahikawa4 Chiba4 Yahaba4 Osaka4 Iruma4 Show all 120
All 120 locations
Target enrolment
to

Trials in this register

51 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Sanofi
Observational
2,500
Kitakyushu-Shi, Takamatsu, Saga, Bunkyo-ku, tabashi City, Niigata
2026-04-01
Recruiting
Sanofi
Phase 3
751
Kamakura, Nishinomiya, Tsu
2026-01-22
Recruiting
Sanofi
Phase 3
751
Bunkyō City, Chikushino-shi, Hachiōji, Kagoshima, Kamakura, Kashiwa, Kobe, Kōriyama
2026-01-16
Recruiting
Sanofi
Phase 3
160
Kōriyama, Sapporo, Yahaba, Higashi-Matsuyama, Kodaira, Kyoto, Tokyo
2026-01-14
Recruiting
Sanofi
Phase 2
144
Nagoya, Tsukuba, Koshigaya, Tokyo
2025-12-29
Recruiting
Sanofi
Phase 2
37
Tokyo
2025-12-02
Recruiting
Sanofi
Observational
1,000
Marugame-shi, Habikino-shi, Hamamatsu
2025-11-17
Recruiting
Sanofi
Phase 2
208
Nishinomiya, Nishihara, Tokyo
2025-11-06
Active, closed
Sanofi
Phase 3
3
Tsuchiura, Kanazawa, Iruma-gun
2025-10-15
Recruiting
Sanofi
Phase 3
980
Asahikawa, Bunkyō City, Chikushino-shi, Chūō, Fukuoka, Kagoshima, Kamakura, Kanazawa
2025-10-08
Recruiting
Sanofi
Phase 3
980
Shizuoka, Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Isehara, Isesaki
2025-10-01
Recruiting
Sanofi
Phase 3
124
Kitakyushu, Hiroshima, Sapporo, Kobe, Kahoku, Uchinada, Kanazawa, Nagaoka, Hirakata
2025-09-26
Recruiting
Sanofi
Phase 4
35
Kawasaki, Hiroshima, Saitama, Tokyo
2025-09-23
Recruiting
Sanofi
Phase 4
218
Ube, Kyoto, Osaka
2025-09-22
Recruiting
Sanofi
Phase 3
942
Kōnan, Nagoya, Toyota, Matsuyama, Fukuoka, Iizuka, Kurume, Kure
2025-09-16
Recruiting
Sanofi
Phase 3
90
Nagoya, Tsuchiura, Kanazawa, Fujisawa, Suita, Iruma, Kofu, Fukuoka
2025-08-18
Recruiting
Sanofi
Phase 3
723
Nagoya, Sapporo, Kobe, Yokohama, Azumino, Shimajiri, Iruma, Koshigaya
2025-08-06
Active, closed
Sanofi
Phase 2
5
Ichikawa, Maebashi, Sapporo, Kobe, Kanazawa, Yahaba, Yokohama, Iruma
2025-07-25
Active, closed
Sanofi
Phase 2
105
Kashiwa, Ōita, Hamamatsu, Hirosaki, Morioka, Nishinomiya
2025-07-07
Recruiting
Sanofi
Phase 2
99
Kashiwa, Ōita, Hamamatsu, Bunkyō City, Hirosaki, Morioka, Nishinomiya
2025-06-03
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Higashi-Matsuyama, Bunkyo-Ku, Kodaira
2025-04-01
Active, closed
Sanofi
Phase 3
231
Ichikawa, Narita, Isehara, Odawara, Yokohama, Suwa, Kusatsu, Fukui
2025-02-12
Active, closed
Sanofi
Phase 3
216
Toyama
2025-02-06
Active, closed
Sanofi
Phase 2
556
Ube
2024-11-07
By invitation
Sanofi
Phase 2
900
Sakaidechō, Chūō, Ube, Fukushima, Kyoto, Miyazaki
2024-09-30
Recruiting
Sanofi
Phase 3
160
Yokohama, Higashi-Matsuyama, Kawagoe, Yaizu, Kodaira, Ōta-ku, Amagasaki, Chiba
2024-08-21
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Sayama, Kawagoe, Yaizu, Bunkyo-Ku, Kodaira, Chiba, Fukuoka, Saga
2024-07-12
Active, closed
Sanofi
Phase 3
1,541
Chitose, Obihiro, Sapporo, Kobe, Sagamihara, Yokohama, Miyagi-gun, Sendai
2024-05-08
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Chiba, Morioka, Sagamihara-shi, Kyoto, Sendai, Moriguchi-shi, Osaka, Kawagoe-shi
2024-04-16
Active, closed
Sanofi
Phase 3
464
Yokohama, Habikino, Sakai, Mibu, Minato, Tachikawa, Hiroshima, Sapporo
2024-02-29
By invitation
Sanofi
Phase 3
90
Isehara, Tsu, Ureshino, Fukuoka
2024-01-03
Active, closed
Sanofi
Phase 3
943
Kōriyama, Asahikawa, Himeji, Sagamihara, Higashi-Matsuyama, Kodaira, Chiba, Fukuoka
2023-12-27
Active, closed
Sanofi
Phase 3
1,655
Kōriyama, Asahikawa, Sapporo, Yahaba, Sagamihara, Higashi-Matsuyama, Kodaira, Tachikawa
2023-12-13
Recruiting
Sanofi
Phase 3
180
Tokyo
2023-10-10
By invitation
Sanofi
Phase 2
70
Okayama
2023-04-05
Active, closed
Sanofi
Phase 2
118
Kashiwa, Okayama
2023-04-05
Active, closed
Sanofi
Phase 2
999
Obihiro, Yokohama, Sakai, Mibu, Tachikawa
2023-04-03
Active, closed
Sanofi
Phase 3
91
Nagoya, Kashihara-shi, Saitama-shi
2023-02-01
Active, closed
Sanofi
Phase 2
68
Nagoya, Kashiwa, Kitakyushu, Sapporo, Kamakura, Shimizu, Bunkyo, Kyoto
2023-01-12
Recruiting
Sanofi
Phase 1/2
542
Kashiwa
2022-11-29
Active, closed
Sanofi
Phase 2
187
Nagaoka, Hamamatsu, Chūō, Fukushima, Osaka, Ōita, Saitama
2022-11-25
Active, closed
Sanofi
Phase 2/3
1,856
Chitose, Obihiro, Sapporo, Sagamihara, Yokohama, Habikino, Sakai, Iruma
2022-08-22
Active, closed
Sanofi
Phase 3
531
Nagoya, Kamogawa, Higashiibaraki, Yahaba, Kamakura, Okayama, Kyoto, Osaka
2022-06-23
Active, closed
Sanofi
Phase 3
104
Sapporo, Kagoshima, Kawasaki, Sendai, Fukuoka, Tokyo
2022-05-03
Active, closed
Sanofi
Phase 3
43
Odawara, Sendai
2022-04-18
Active, closed
Sanofi
Phase 3
122
Fukuoka, Tokyo
2022-03-11
Recruiting
Sanofi
Phase 3
284
Matsudo, Urayasu, Sapporo, Yokohama, Habikino, Sakai, Izumo, Tachikawa
2022-02-15
Active, closed
Sanofi
Phase 3
337
Nagoya, Kamogawa-shi, Maebashi, Higashiibaraki-gun, Okayama, Sunto-gun, Shibuya-ku
2020-06-16
Active, closed
Sanofi
Observational
1,860
Sagamihara, Yokohama, Tsu, Habikino, Fuchū, Fukuoka, Fukuyama-shi, Hiroshima
2019-08-15
Active, closed
Sanofi
Observational
955
Nagakute-shi, Obihiro-shi, Sapporo, Hirakata-shi, Koshigaya-shi, Shimotsuga-gun, tabashi City, Amagasaki-shi
2019-06-11
Active, closed
Sanofi
Phase 3
475
Nagoya, Higashiibaraki-gun, Konan-ku, Yokohama-shi, Kumamoto, Sendai, Okayama, Sunto-gun, Shibuya-ku
2017-12-07
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-japan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Japan?

21 of the 51 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 51 studies
PhaseStudiesRecruitingShare
Phase 3301258.8%
Phase 213425.5%
Observational427.8%
Phase 4223.9%
Phase 1/2112%
Phase 2/3102%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Sanofi5121

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Dermatitis Atopic (6) Asthma (4) Multiple Sclerosis (3) Plasma Cell Myeloma (3) Ulcerative Colitis (3) Crohn's Disease (3) Polyneuropathy, Inflammatory Demyelinating, Chronic (2) Chronic Obstructive Pulmonary Disease (2) Hidradenitis Suppurativa (2) Chronic Rhinosinusitis With Nasal Polyps (2) Fabry Disease (2) Colitis Ulcerative (2) Type 1 Diabetes Mellitus (2) Lung Transplant Rejection (1) Gaucher's Disease Type III (1)
→

Browse trials by site location

Sapporo (12) Yokohama (10) Fukuoka (10) Nagoya (9) Tokyo (8) Kodaira (6) Kyoto (6) Kashiwa (6) Sendai (5) Sagamihara (5) Okayama (5) Kanazawa (5) Kobe (5) Kamakura (5)
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.